Format
Sort by
Items per page

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 71

1.

Comparative gene expression analysis of a chronic myelogenous leukemia cell line resistant to cyclophosphamide using oligonucleotide arrays and response to tyrosine kinase inhibitors.

Bao F, Polk P, Nordberg ML, Veillon DM, Sun A, Deininger M, Murray D, Andersson BS, Munker R.

Leuk Res. 2007 Nov;31(11):1511-20. Epub 2007 Apr 2.

PMID:
17403535
2.

Triptolide inhibits Bcr-Abl transcription and induces apoptosis in STI571-resistant chronic myelogenous leukemia cells harboring T315I mutation.

Shi X, Jin Y, Cheng C, Zhang H, Zou W, Zheng Q, Lu Z, Chen Q, Lai Y, Pan J.

Clin Cancer Res. 2009 Mar 1;15(5):1686-97. doi: 10.1158/1078-0432.CCR-08-2141. Epub 2009 Feb 24.

3.

Nilotinib: a second-generation tyrosine kinase inhibitor for the treatment of chronic myelogenous leukemia.

Deremer DL, Ustun C, Natarajan K.

Clin Ther. 2008 Nov;30(11):1956-75. doi: 10.1016/j.clinthera.2008.11.014. Review.

PMID:
19108785
4.

New mutations detected by denaturing high performance liquid chromatography during screening of exon 6 bcr-abl mutations in patients with chronic myeloid leukemia treated with tyrosine kinase inhibitors.

Mascarenhas CC, Cunha AF, Miranda EC, Zulli R, Silveira RA, Costa FF, Pagnano KB, De Souza CA.

Leuk Lymphoma. 2009 Jul;50(7):1148-54. doi: 10.1080/10428190902930496.

PMID:
19557636
5.

Inhibition of Abl tyrosine kinase enhances nerve growth factor-mediated signaling in Bcr-Abl transformed cells via the alteration of signaling complex and the receptor turnover.

Koch A, Scherr M, Breyer B, Mancini A, Kardinal C, Battmer K, Eder M, Tamura T.

Oncogene. 2008 Aug 7;27(34):4678-89. doi: 10.1038/onc.2008.107. Epub 2008 Apr 21.

PMID:
18427551
6.

Optimizing outcomes for patients with advanced disease in chronic myelogenous leukemia.

Giles FJ, DeAngelo DJ, Baccarani M, Deininger M, Guilhot F, Hughes T, Mauro M, Radich J, Ottmann O, Cortes J.

Semin Oncol. 2008 Feb;35(1 Suppl 1):S1-17; quiz S18-20. doi: 10.1053/j.seminoncol.2007.12.002. Review.

PMID:
18346528
7.

Instability of BCR-ABL gene in primary and cultured chronic myeloid leukemia stem cells.

Jiang X, Saw KM, Eaves A, Eaves C.

J Natl Cancer Inst. 2007 May 2;99(9):680-93.

PMID:
17470736
8.

Drug evaluation: Nilotinib - a novel Bcr-Abl tyrosine kinase inhibitor for the treatment of chronic myelocytic leukemia and beyond.

Jabbour E, Cortes J, Giles F, O'Brien S, Kantarijan H.

IDrugs. 2007 Jul;10(7):468-79.

PMID:
17642017
9.

Gene expression analysis of BCR/ABL1-dependent transcriptional response reveals enrichment for genes involved in negative feedback regulation.

Håkansson P, Nilsson B, Andersson A, Lassen C, Gullberg U, Fioretos T.

Genes Chromosomes Cancer. 2008 Apr;47(4):267-75. doi: 10.1002/gcc.20528.

PMID:
18181176
10.

Expression analysis of PCNA gene in chronic myelogenous leukemia--combined application of siRNA silencing and expression arrays.

Merkerova M, Bruchova H, Brdicka R.

Leuk Res. 2007 May;31(5):661-72. Epub 2006 Oct 27.

PMID:
17070905
11.

Dynamics of BCR-ABL kinase domain mutations in chronic myeloid leukemia after sequential treatment with multiple tyrosine kinase inhibitors.

Cortes J, Jabbour E, Kantarjian H, Yin CC, Shan J, O'Brien S, Garcia-Manero G, Giles F, Breeden M, Reeves N, Wierda WG, Jones D.

Blood. 2007 Dec 1;110(12):4005-11. Epub 2007 Sep 4.

12.
13.

Hematological and molecular response evaluation of CML patients on imatinib.

Gupta A, Prasad K.

J Assoc Physicians India. 2007 Feb;55:109-13.

PMID:
17571739
14.

Sorafenib induces apoptosis specifically in cells expressing BCR/ABL by inhibiting its kinase activity to activate the intrinsic mitochondrial pathway.

Kurosu T, Ohki M, Wu N, Kagechika H, Miura O.

Cancer Res. 2009 May 1;69(9):3927-36. doi: 10.1158/0008-5472.CAN-08-2978. Epub 2009 Apr 14.

15.

N-acetyl cysteine enhances imatinib-induced apoptosis of Bcr-Abl+ cells by endothelial nitric oxide synthase-mediated production of nitric oxide.

Rakshit S, Bagchi J, Mandal L, Paul K, Ganguly D, Bhattacharjee S, Ghosh M, Biswas N, Chaudhuri U, Bandyopadhyay S.

Apoptosis. 2009 Mar;14(3):298-308. doi: 10.1007/s10495-008-0305-7.

PMID:
19153832
17.

[Detection of ABL kinase domain point mutations in chronic myeloid leukemia patients receiving imatinib treatment].

Ouyang Z, DU QF, Liu XL, Zhang S, Zhu HQ, Gong JM, Song LL, Ouyang LY, Liu Z.

Nan Fang Yi Ke Da Xue Xue Bao. 2008 May;28(5):704-6. Chinese.

18.

Tasigna for chronic and accelerated phase Philadelphia chromosome--positive chronic myelogenous leukemia resistant to or intolerant of imatinib.

Hazarika M, Jiang X, Liu Q, Lee SL, Ramchandani R, Garnett C, Orr MS, Sridhara R, Booth B, Leighton JK, Timmer W, Harapanhalli R, Dagher R, Justice R, Pazdur R.

Clin Cancer Res. 2008 Sep 1;14(17):5325-31. doi: 10.1158/1078-0432.CCR-08-0308.

19.

Nilotinib: a new tyrosine kinase inhibitor for the treatment of chronic myelogenous leukemia.

Jarkowski A, Sweeney RP.

Pharmacotherapy. 2008 Nov;28(11):1374-82. doi: 10.1592/phco.28.11.1374. Review.

PMID:
18956997
20.

Distinct molecular phenotype of malignant CD34(+) hematopoietic stem and progenitor cells in chronic myelogenous leukemia.

Kronenwett R, Butterweck U, Steidl U, Kliszewski S, Neumann F, Bork S, Blanco ED, Roes N, Gräf T, Brors B, Eils R, Maercker C, Kobbe G, Gattermann N, Haas R.

Oncogene. 2005 Aug 11;24(34):5313-24.

PMID:
15806158

Supplemental Content

Support Center